China's independent research and development of 13-price pneumonia combined vaccine the first batch of products were approved for market

Watson Biotechnology Co., Ltd.
subsidiary Yuxi Watson Biotechnology Co., Ltd. produced the first batch of 13-price pneumococcal polysaccharide combination vaccine (hereinafter referred to as "13-price pneumonia combined vaccine"), has been issued by the State Drug Administration "Biological Products Approval Certificate", which marks the product has been officially listed for sale.Streptococcus pneumoniae is the most common cause of invasive diseases as well as pneumonia and upper respiratory tract infections. More than one million people worldwide die each year from Streptococcus pneumoniae, a high-risk group of pneumococcal diseases in children born to two years of age who lack the corresponding antibodies.Watson Bio is the first company in China and the second in the world to be licensed for the 13-price pneumonia combined vaccine. The 13-price pneumonia-binding vaccine, developed by the company, is China's first self-developed 13-price pneumonia-binding vaccine for infants and children between the ages of 6 weeks and 5 years (before their 6th birthday) and can be used to prevent 13 serotypes (type 1, type 3, Infectious diseases caused by pneumococcal bacteria type 4, type 5, type 6A, type 6B, type 7F, type 9V, type 14, type 18C, type 19A, type 19F and type 23F.It is reported that this time Watson Bio obtained the State Drug Administration issued the "Biological Products Issue Certificate" of the first batch of 141,119 products. Obtaining a certificate of approval means that the product is ready for sale. (ChinaNews.com)